# Bowel Regimen Recommendations

**For Patients With a Functioning Gastrointestinal Tract**

---

## Pharmacologic Classes

- **Miralax** – Osmotic laxative  
- **Sennokot** – Stimulant laxative  
- **Milk of Magnesia** – Osmotic laxative  
- **Bisacodyl Suppository** – Stimulant laxative  
- **Lactulose** – Osmotic laxative  

---

## Initial Regimen (At Admission)

- Start:
  - **Sennokot** 2 tablets BID  
  - **Miralax** 17 g daily  

---

## Escalation Based on Time Without Bowel Movement

### After 48 Hours

- **Normal Renal Function:**  
  - Add **Milk of Magnesia** 15 mL PO TID  

- **Impaired Renal Function:**  
  - Add **Lactulose** 20 g PO TID  

---

### After 72 Hours

- **Normal Renal Function:**  
  - Increase **Milk of Magnesia** to 30 mL PO TID  
  - Add **Bisacodyl Suppository** 10 mg PR ×1  

- **Impaired Renal Function:**  
  - Add **Bisacodyl Suppository** 10 mg PR ×1  

---

### After 96 Hours

- Add **SMOG Enema** 120 mL PR ×1  
- **Consider** abdominal imaging (**KUB**)  

---

## Monitoring: Red Flags for Ileus or Obstruction

**If constipation is accompanied by any of the following symptoms, obtain a KUB to assess for ileus or obstruction:**

- Abdominal distention, discomfort, or firmness  
- Decreased or absent flatus  
- Increased belching or hiccups  
- Nausea or vomiting  

---

# Bowel Regimen for Non-Functioning Gastrointestinal Tract

> Use this section if an **ileus is present** on clinical exam or imaging.

---

## Initial Management

- Place **NG tube** to low wall suction  
- Make patient **NPO**  
- Initiate **IV fluids**  
- Monitor **electrolytes as needed**  
- Continue **per rectal** bowel regimen  
- Encourage **ambulation** (if appropriate)  
- **Repeat KUB** PRN to monitor gas pattern  
- Discontinue or minimize:
  - Opioids  
  - Anticholinergics  
  - Dopamine agonists  
  - Anti-serotonergics  

---

## Advanced Pharmacologic Interventions

### Ogilvie’s Syndrome (Confirmed on Imaging)

- **Neostigmine**
  - Can only be given on **10N**
  - **Use caution** in patients with **anastomosis**

---

### Postoperative Ileus or Opioid-Induced Constipation

#### Oral Naloxone

- Initial dose: **2 mg PO TID**  
- Max dose: **4 mg PO TID**  
- Max duration: **48 hours**  
- **Monitor for opioid reversal**, especially in liver disease

#### Methylnaltrexone

- **Dose:** 12 mg SQ ×1  
- May repeat after 24 hours if no resolution  
- **Use only if:**
  - Imaging confirms **no obstruction**  
  - Oral naloxone **has failed**
- **Must discuss with attending before ordering**  
- **Use caution** in patients with **an anastomosis**

---

# Management of Diarrhea

---

## Initial Steps

- **Stop** all bowel regimen agents  
- **Monitor electrolytes**

---

## If C. difficile Negative

- **Imodium:** 4 mg q6h PRN  
- **Fiber supplementation:**

  - **Without feeding tube:**  
    - **Psyllium:** 2 caps daily (max 5 caps QID)  

  - **With feeding tube:**  
    - **Nutrisource Fiber:** 1 packet daily (max 6 packets/day; order under tube feeds)

- Titrate **dose and frequency** as needed

---

## References

1. Yang A, Lam T, Jierjian E, et al. *An Evaluation of docusate monotherapy and the prevention of opioid-induced constipation after surgery.* J Pain Palliat Care Pharmacother. 2022; 36(1):18–23.  
2. Gathers K, Fawad K, Petros K. *Evaluation of methylnaltrexone bromide for the treatment of postoperative ileus.* Crit Care Med. 2013;41(12):929.  
3. Chamie K, Golla V, Lenis AT, et al. *Peripherally Acting μ-Opioid Receptor Antagonists in the Management of Postoperative Ileus: a Clinical Review.* J Gastrointest Surg. 2020. https://doi.org/10.1007/s11605-020-04671-x  
4. Valle RG, Godoy FL. *Neostigmine for acute colonic pseudo-obstruction: a meta-analysis.* Ann Med Surg (Lond). 2014;3(3):60–64.  
5. Dudi-Venkata NN, Kroon HM, Bedrikovetski S, et al. *Impact of STIMUlant and osmotic LAXatives (STIMULAX trial) on gastrointestinal recovery after colorectal surgery: randomized clinical trial.* Br J Surg. 2021 Jul 23;108(7):797–803.  
6. Beavers J, Orton L, Atchison L, et al. *The Efficacy and Safety of Methylnaltrexone for the Treatment of Postoperative Ileus.* Am Surg. 2022; 88(3):409–413.  
7. Gibson CM, Pass SE. *Enteral naloxone for the treatment of opioid-induced constipation in the medical intensive care unit.* J Crit Care. 2014; 29(5):803–807.  
8. Merchan C, Altshuler D, Papadopoulos J. *Methylnaltrexone Versus Naloxone for Opioid-Induced Constipation in the Medical Intensive Care Unit.* Ann Pharmacother. 51(3):203–208.  
9. Liu M, Wittbrodt E. *Low-dose oral naloxone reverses opioid-induced constipation and analgesia.* J Pain Symptom Manage. 2002; 23(1):48–553.  

---

## Reviewed November 2024 By

- Caroline Banes, DNP, APRN, ACNP-BC  
- Jennifer Beavers, PharmD, BCPS  
- Jennifer Emerson, PharmD  
- Bethany Evans, MSN, ACNP-BC  
- Chelsea Tasaka, PharmD, BCCCP  
- Caroline Jackson, PharmD
